{"name":"Italfarmaco","slug":"italfarmaco","ticker":"","exchange":"","domain":"italfarmaco.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Duvyzat first approved","drug":"Duvyzat","drugSlug":"givinostat","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Female Contraceptive","genericName":"Female Contraceptive","slug":"female-contraceptive","indication":"Contraception / prevention of pregnancy","status":"marketed"},{"name":"Duvyzat","genericName":"GIVINOSTAT","slug":"givinostat","indication":"Duchenne muscular dystrophy (DMD)","status":"marketed"},{"name":"Phlebotonic","genericName":"Phlebotonic","slug":"phlebotonic","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Female Contraceptive","genericName":"Female Contraceptive","slug":"female-contraceptive","phase":"marketed","mechanism":"Female contraceptives prevent pregnancy by suppressing ovulation and altering the reproductive tract environment through hormonal mechanisms.","indications":["Contraception / prevention of pregnancy"],"catalyst":""},{"name":"Duvyzat","genericName":"GIVINOSTAT","slug":"givinostat","phase":"marketed","mechanism":"Duvyzat works by blocking enzymes that compact chromatin and silence genes.","indications":["Duchenne muscular dystrophy (DMD)"],"catalyst":""},{"name":"Phlebotonic","genericName":"Phlebotonic","slug":"phlebotonic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOQWJjbXUtX0pIZGFmWHVrNW5CSTJDYjIzVWFfMFFXZ1ZBQW5lYlFSaFpCdFo5UzFUdi1zUVBNcU5IN19DWUozbXlDWW9hZUdwUk96VGkxSEoyOFM5TVBkX0taY05nd2xRMmw5enlqUkN4V2ZVb0Rxd3JOVVVWWkd2RXpSM2JlcUpha29QRjBKSmFRbFltY0xyaHQ4clA2eVotOHNVZXhDWVA1VVZlMW9YR1hYX3E2VF8tYlBqcnowUWJ6am03d2UyemgtWllpMTl4YlVMTEFwVGpBN3k1aVAxdTBmc3RldVFRVDViaF96LUVYS3lHNmlvS0tUZHNwMVRUSmlzN19QWWpkQWEybnVTMGR5TDlieWZmckJNMDZTcG52eG8?oc=5","date":"2025-12-24","type":"deal","source":"Business Wire","summary":"Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease - Business Wire","headline":"Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collabora","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNbVp0Y2VILTNHZXVxLS1oSW5mcXBJOWhvMC1VM21MbURJRVpLTktSTHl4MzVvSHRsQmtock5YaHNCMVdZQ2NEcG5NcVROLW9FU1pfbmcxeldMX2Nvc3pSdUM3MFlVZUpUazRCZ2ZtbHA5VURvcHhTM3Uta3pEbVkweGlrU05OTnFvRnktUk1iX3IzcXJra3c?oc=5","date":"2025-10-09","type":"pipeline","source":"The Pharma Letter","summary":"Italfarmaco appoints Francesco Di Marco as CEO - The Pharma Letter","headline":"Italfarmaco appoints Francesco Di Marco as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPaG1neHBwRTBlQWVWWTFvTjk5U3VURHlpeVV6ZjlwaFhvT1VzVW5PWDZtSlcwUG9CeHR0RjdvTGdXMS1uNGQwYXotUGthRXM3TnBLVHR4bU1CbjQzQkhzaGJhZVBweWpuQkJ2YUs2UFowcmtqem5Nd0tzUXk4a2N2Y2tmbDdLWTlWUldITjJJS2EyeVFhQS1idTJudGdhWFBySUxxUEJfZWRXV2x6V0JwSFZSQlFoa1Y2UG9OTGZpMXhqZEpXUkYtZWVmX1JUb0xuUmhtVQ?oc=5","date":"2025-10-09","type":"pipeline","source":"GlobeNewswire","summary":"Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer - GlobeNewswire","headline":"Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPT0h6S1VoR1o4c3BfQnFoUTRiMDhfNHVLbUxENzJVNXUzcGx3SzBiUHJoRDZNc3ladFlFTl9paDQxN09xQXBxRXZTaEhzVzRmX2o3OGlYaU9vTnNrSXhIeGIyMm9GeW9sWlIwam05ZmVCaFltLUZyWkxBYnBLbFpXZzIwUlZXTGNQTEpXbmgydzBncEUwYlV0RkxuUWdFWl8tRVE?oc=5","date":"2025-09-16","type":"pipeline","source":"Yahoo Finance","summary":"Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil - Yahoo Finance","headline":"Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBkZGl1Y1M4Y3d5TXpnQXZZZW80ZkJ2XzMtdVI0b2JiU1lRbVVqQ05CYXpFNjhtbmR2VUlESjQwQm40YTJUOC16ZGdXUGxjOVp2VE9j?oc=5","date":"2025-06-09","type":"pipeline","source":"FirstWord Pharma","summary":"Italfarmaco's Duvyzat scores conditional EU nod for DMD treatment - FirstWord Pharma","headline":"Italfarmaco's Duvyzat scores conditional EU nod for DMD treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOT1NzanBmWjZrdXE2UDVWMnkwS3dNcFV5dTItWWY1bTRCNVNjTzlrQXRZMnFvc1Z4OTRHeGZWME1EZ1dwdWVCYXNIU1pXUUktaHU4MUhUVF9vcF9ieXZEWEt6S3AyWnhKNW5weHFqeDBKQTJTZTVRbERWRWRQVEphMi05YndKWUtYRGktbXRGSURDUjRfTGUtZnJMNk9qRy1HbzR2emdoSmg0NW8?oc=5","date":"2025-05-06","type":"regulatory","source":"Contract Pharma","summary":"Italfarmaco’s Givinostat Granted Fast Track Designation by FDA - Contract Pharma","headline":"Italfarmaco’s Givinostat Granted Fast Track Designation by FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE81QldrNFM3Um1RSTFlVHl1WF9Ld21BbThuY29WOTBmNV90QWladzBMZlpURnkySUkzckNVMkJkMm1qOXlTaHg2enBTQ29mSFlXMHNwVmVCMjNwenhVaS1mSUgxN1Nvc2NSRXpKMXEzMEhUNHBEZXpHYldn?oc=5","date":"2025-04-28","type":"pipeline","source":"pharmaphorum","summary":"Italfarmaco closes on EU okay for Duchenne drug - pharmaphorum","headline":"Italfarmaco closes on EU okay for Duchenne drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaVJlSzBMQ0VIRWg5UHl5cExac1cta1l1Ty1IUFJYbER5WGNYcG02U0FlMV9IN05hNzlXRl9XMzI1dVg3amRtVzJTczNEUmlQR3dTRlhUUGY2X2ZZRFFxUlhta3hHSGltai11TVhSYmVhRlB2TDJTRjkzNlY0eGx3LUtxQkNOYWkzQ3FGTG5paTV3VHlaeG5WN0JCeWg3cy0ycks5NExDZkVzS0xibmVFYW55MHJqampld08weGgxOTZYdmxUWU9PVTNJT3pqMVhYcURNNGdwT3MzQQ?oc=5","date":"2025-03-05","type":"earnings","source":"PR Newswire","summary":"ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts - PR Newswire","headline":"ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPejBqSkVHdTRWbXN4ay1XalExcHZ1THdZWDdWZXBfMklSOFV4bnVhTS1xSjJLT0IyME53OWV2aTlJRUhjbEFZN0E0M2xDdm80aXh2WXE4bVp6Q1dxcXFUWU5ld1JoeWtNamZ1RGk5NU9rTzRpVGNrUEVLWnlBT190RTV5RHRvdmwyelYzQS1zaXlTVVRST25NR1JYZWctcHZfZFYyel9n?oc=5","date":"2025-01-08","type":"regulatory","source":"PMLiVE","summary":"MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy - PMLiVE","headline":"MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNZVd4V0ZkX1ZmcHVMYUhTckdmTlV6TUs4VFhRWXphcy1GNDRuNUM1T2lKRFJieXNpWGdUVXo3bUo3amVwNzBzVGw5NUtORFJoSWdpVkFnWUFMU2c5N0NCUlNKaFhmUzd4ZjZtbjRNSndVMDhCR1lJNUlpQ280UGNNM3kyZF9ZREZNQWVBRy13TVBMeHhCTjExaXBmYlF5RFFmTG5VbmJXSFdxNFdFYW03SjlsbVlrN1JTdmJ3bklB?oc=5","date":"2024-03-22","type":"regulatory","source":"Fierce Pharma","summary":"Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta - Fierce Pharma","headline":"Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUUpzaFoxZ0xZNVRMM051ZG1kSkd0VG5YbkVHT1VWdTA2eHdPd2FxZ0pFdzVGUElheUQ0SndsU0dXNEhwbGNpb1dERmE1RTNGV2IxMmZHcHBDQi1sRUtib1JoN1BVa1BWRUlVU1pRaWQyNzYxb2QtTFRDeHhHcl9zRG9pTm1pM2l3MWpUWllFZW03NVh5VWZQNnZfTDdMTXEyd2VKWmszZzR3LVQ2Uy1tQlpNVjNfeXloaHJJWnh6SjFxcHQyYjhzUg?oc=5","date":"2024-03-21","type":"regulatory","source":"Reuters","summary":"US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder - Reuters","headline":"US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbkhGb2RqVVl6UHVDRzFNRGhFUU1Ja2dLSncwN05EVHlJSHBuSU1TWTR3ajdYdF9KaU5NN0Fzd256OU90ejg1bk9CRmFiRzlLTkREVWNmYjI5MlluRmlMWWl0WUUtSnJSd21hcjJjNTdLWjE2Q2pvQnBLend2SGNWcmhwcHJ1eWhaMUpTaWJlMzh2cHNEM1NWRFBuVWxKY3Y0TWJRVzNfM0VjVnJlYzZlOW8zQzVTeXAtTXZTVQ?oc=5","date":"2021-03-16","type":"pipeline","source":"Drug Delivery Business","summary":"Italfarmaco, Luye enter commercialization pact for transdermal Alzheimer’s treatment - Drug Delivery Business","headline":"Italfarmaco, Luye enter commercialization pact for transdermal Alzheimer’s treatment","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}